[go: up one dir, main page]

NO963097D0 - Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4 - Google Patents

Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4

Info

Publication number
NO963097D0
NO963097D0 NO963097A NO963097A NO963097D0 NO 963097 D0 NO963097 D0 NO 963097D0 NO 963097 A NO963097 A NO 963097A NO 963097 A NO963097 A NO 963097A NO 963097 D0 NO963097 D0 NO 963097D0
Authority
NO
Norway
Prior art keywords
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
vla
Prior art date
Application number
NO963097A
Other languages
English (en)
Other versions
NO319867B1 (no
NO963097L (no
Inventor
Mary M Bendig
Olivier J Leger
Jose W Saldanha
Tarran S Jones
Original Assignee
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc filed Critical Athena Neurosciences Inc
Publication of NO963097D0 publication Critical patent/NO963097D0/no
Publication of NO963097L publication Critical patent/NO963097L/no
Publication of NO319867B1 publication Critical patent/NO319867B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19963097A 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff. NO319867B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (3)

Publication Number Publication Date
NO963097D0 true NO963097D0 (no) 1996-07-24
NO963097L NO963097L (no) 1996-09-24
NO319867B1 NO319867B1 (no) 2005-09-26

Family

ID=22684288

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19963097A NO319867B1 (no) 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Country Status (21)

Country Link
EP (2) EP1759709B1 (no)
JP (5) JP4115517B2 (no)
KR (1) KR100367948B1 (no)
CN (1) CN1211123C (no)
AT (1) ATE333895T1 (no)
AU (1) AU703152B2 (no)
CA (1) CA2182013C (no)
DE (2) DE69535133T2 (no)
DK (2) DK1759709T3 (no)
ES (2) ES2270425T3 (no)
FI (1) FI117509B (no)
FR (1) FR06C0024I2 (no)
HU (1) HU220799B1 (no)
LU (1) LU91271I2 (no)
MX (1) MX9602971A (no)
NL (1) NL300238I2 (no)
NO (3) NO319867B1 (no)
NZ (1) NZ279730A (no)
PL (1) PL181827B1 (no)
PT (1) PT804237E (no)
WO (1) WO1995019790A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
DE60020955T2 (de) 1999-04-22 2006-05-11 Biogen Idec Ma Inc., Cambridge Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
GEP20063774B (en) 1999-06-01 2006-03-27 Biogen Idec Inc Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001043774A1 (en) * 1999-12-16 2001-06-21 Biogen, Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
BRPI0209792B8 (pt) 2001-04-13 2021-05-25 Biogen Idec Inc anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1572748B1 (en) * 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
CN101102792A (zh) * 2004-11-19 2008-01-09 比奥根艾迪克Ma公司 治疗多发性硬化
US20070122404A1 (en) * 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
EP2034830B1 (en) 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0814252B8 (pt) * 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
MX2010004056A (es) 2007-12-13 2010-05-03 Tokuyama Corp Composicion fotocromica curable.
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP4032912B1 (en) 2010-04-16 2025-05-28 Biogen MA Inc. Anti-vla-4 antibodies
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3635093A1 (en) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
SG44845A1 (en) * 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
HU220799B1 (hu) 2002-05-28
DE69535133D1 (de) 2006-09-07
MX9602971A (es) 1998-01-31
NO2006008I2 (no) 2009-06-15
NO2017040I2 (no) 2018-08-28
FR06C0024I1 (no) 2006-10-13
FI117509B (fi) 2006-11-15
PT804237E (pt) 2006-10-31
ATE333895T1 (de) 2006-08-15
DE122006000043I1 (de) 2007-02-15
DE69535133T2 (de) 2008-08-21
WO1995019790A1 (en) 1995-07-27
DK0804237T3 (da) 2006-10-16
JP5487382B2 (ja) 2014-05-07
NO2017040I1 (no) 2017-08-01
NO319867B1 (no) 2005-09-26
HU9602019D0 (en) 1996-09-30
CA2182013C (en) 2007-07-17
KR100367948B1 (ko) 2003-07-12
EP0804237A4 (en) 2003-04-16
ES2424292T3 (es) 2013-09-30
EP1759709A1 (en) 2007-03-07
JP2013173738A (ja) 2013-09-05
LU91271I2 (fr) 2006-10-02
NL300238I1 (no) 2006-10-02
NZ279730A (en) 1998-04-27
NO963097L (no) 1996-09-24
HUT75129A (en) 1997-04-28
JP2009235078A (ja) 2009-10-15
KR970700513A (ko) 1997-02-12
CN1140413A (zh) 1997-01-15
PL181827B1 (pl) 2001-09-28
FI962958L (fi) 1996-09-24
AU703152B2 (en) 1999-03-18
JP2013165718A (ja) 2013-08-29
FR06C0024I2 (fr) 2009-01-02
EP0804237B1 (en) 2006-07-26
NO2006008I1 (no) 2006-08-07
PL315634A1 (en) 1996-11-25
AU1696095A (en) 1995-08-08
CA2182013A1 (en) 1995-07-27
CN1211123C (zh) 2005-07-20
ES2270425T3 (es) 2007-04-01
EP1759709B1 (en) 2013-02-27
JPH09508272A (ja) 1997-08-26
JP2006045237A (ja) 2006-02-16
FI962958A0 (fi) 1996-07-24
NL300238I2 (nl) 2007-05-01
JP4115517B2 (ja) 2008-07-09
EP0804237A1 (en) 1997-11-05
DK1759709T3 (da) 2013-06-10
EP0804237B8 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
FI962958A0 (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
FI961285A0 (fi) CD40:n vasta-aineita
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE59609954D1 (de) Katalytisch wirksame aktivatorkomplexe für persauerstoffverbindungen
ATE531812T1 (de) Humanisierung von nager-antikörpern
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
IL141158A0 (en) A humanized immunoglobulin which binds to human von willebrand factor
DE69103214D1 (de) Verfahren zur Reinigung von Glycin.
NO179328C (no) Antistoffer mot retinoblastom-genprodukt, anvedelse derav samt murint hybridom
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCX Expiry of an spc

Spc suppl protection certif: 2006008